Viridian Therapeutics, Inc.\DE (VRDN) Payables (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Payables of $13.3 million for Q1 2026, up 242.59% year-over-year from $3.9 million in Q1 2025, and up 53.32% quarter-over-quarter from $8.7 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Payables (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Payables history runs 14 years deep, the most recent figure standing at $13.3 million for Q1 2026.
- In Q1 2026, Payables rose 242.59% year-over-year to $13.3 million; the TTM figure through Mar 2026 stood at $13.3 million (up 242.59% YoY), while the FY2025 annual figure was $8.7 million, up 305.18% from the prior year.
- Payables for Q1 2026 stood at $13.3 million, up from $8.7 million in the prior quarter.
- The five-year high for Payables was $14.2 million in Q4 2022, with the low at $2.1 million in Q4 2024.
- The 5-year median for Payables is $4.1 million (2023), against an average of $6.5 million.
- The sharpest annual moves came in 2022 and 2023: Payables soared 511.16% in 2022, then plunged 84.27% in 2023.
- Viridian Therapeutics, Inc.\DE's Payables stood at $14.2 million in 2022, then slumped by 84.27% to $2.2 million in 2023, then dropped by 4.29% to $2.1 million in 2024, then surged by 305.18% to $8.7 million in 2025, then soared by 53.32% to $13.3 million in 2026.
- Business Quant data shows VRDN's Payables at $13.3 million in Q1 2026, $8.7 million in Q4 2025, and $10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.65 Mn |
| Mar 31, 2026 | 13.31 Mn |
| Dec 31, 2025 | 8.68 Mn |
| Sep 30, 2025 | 10.06 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 2.14 Mn |
| Sep 30, 2024 | 6.34 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2023 | 2.24 Mn |
| Sep 30, 2023 | 3.74 Mn |
| Jun 30, 2023 | 4.13 Mn |
| Mar 31, 2023 | 7.87 Mn |
| Dec 31, 2022 | 14.23 Mn |
| Sep 30, 2022 | 12.15 Mn |
| Jun 30, 2022 | 4.06 Mn |
| Mar 31, 2022 | 2.54 Mn |
| Dec 31, 2021 | 2.33 Mn |
| Sep 30, 2021 | 3.73 Mn |